YENOM NOTICIAS

Qué está moviendo el mercado.

Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.

ABVC
Limpiar

Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.

nasdaq.comNEGATIVO

Pre-Market Movers: TNON, ADTX, LNAI See Sharp Moves

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell t…

nasdaq.comPOSITIVO

Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance

(RTTNews) - Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate updates and investor momentum. Plus Therapeut…

finance.yahoo.comPOSITIVO

ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. ABVC BioPharma, Inc. is one of them. ABVC BioPharma, Inc. (NASDAQ:ABVC) tops our list for being one of the best penny stocks. It is a cli…

nasdaq.comPOSITIVO

Tuesday Sector Leaders: Biotechnology, Oil & Gas Exploration & Production Stocks

In trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 4.4%. Leading the group were shares of ProKidney, up about 366.7% and shares of ABVC BioPharma up about 25.1% on the day. Also showing relative stren…

chartmill.comPOSITIVO

Which stocks are moving on Monday?

Enable social media cookies to share Which stocks are moving on Monday? By Mill Chart Last update: Apr 7, 2025 Here are the top movers in Monday's session, showcasing the stocks with significant price changes. Today's top gainers TickerCha…

chartmill.comPOSITIVO

Keep an eye on the top gainers and losers in Monday's session.

Enable social media cookies to share Keep an eye on the top gainers and losers in Monday's session. By Mill Chart Last update: Apr 7, 2025 Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top ga…

globenewswire.comPOSITIVO

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

FREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hemat…

globenewswire.comPOSITIVO

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems),…

globenewswire.comPOSITIVO

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to im…

globenewswire.comPOSITIVO

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

FREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire– ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems),…

globenewswire.comPOSITIVO

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

FREMONT, CA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology,…

globenewswire.comPOSITIVO

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solu…

globenewswire.comPOSITIVO

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

FREMONT, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire– ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, t…

globenewswire.comPOSITIVO

ABVC Executes Cooperation Agreement for Strategic Investments

FREMONT, CA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmo…

globenewswire.comPOSITIVO

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

FREMONT, CA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hemat…

globenewswire.comPOSITIVO

ABVC Corporate Update and CEO's Letter to Shareholders

FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hemato…

globenewswire.comPOSITIVO

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

FREMONT, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, neurology, and ophthalmology, a…

globenewswire.comPOSITIVO

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

FREMONT, CA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neurology, and ophthalmology, today…

globenewswire.comPOSITIVO

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

FREMONT, CA, July 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hemat…

globenewswire.comPOSITIVO

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

FREMONT, CA, July 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hemat…

globenewswire.comPOSITIVO

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

FREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmo…

globenewswire.comPOSITIVO

ABVC BioPharma Announces Reverse Stock Split

FREMONT, CA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hemato…

globenewswire.comPOSITIVO

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

FREMONT, CA, July 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology,…

globenewswire.comPOSITIVO

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

FREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today annou…

globenewswire.comPOSITIVO

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announ…

globenewswire.comPOSITIVO

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neuropsychiatric conditi…

globenewswire.comPOSITIVO

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

FREMONT, CA, June 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and…

globenewswire.comPOSITIVO

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS) disorde…

globenewswire.comNEGATIVO

ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder

FREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announ…

globenewswire.comPOSITIVO

ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF

Fremont, CA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today annou…

globenewswire.comNEGATIVO

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

FREMONT, CA, April 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today anno…

globenewswire.comPOSITIVO

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

Fremont, CA, April 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today annou…

globenewswire.comPOSITIVO

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

FREMONT, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve he…

globenewswire.comNEGATIVO

ABVC BioPharma Provides 2023 Pipeline Update

FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provid…

globenewswire.comPOSITIVO

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announ…

globenewswire.comPOSITIVO

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

FREMONT, CA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today annou…